(Q45236388)

English

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Efstathios Kastritis

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Athanasios Dimopoulos

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

E Efstathiou

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

A Kostakopoulos

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

C Deliveliotis

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

N Antoniou

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

D Skarlos

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

C Papadimitriou

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

A Bamias

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

126-130

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Critical evaluation of hormonal therapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.08.041

7 January 2021

Identifiers

10.1016/J.UROLOGY.2004.08.041

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45236388&oldid=2070932838"